HK1025317A1 - Quinoxalinediones - Google Patents

Quinoxalinediones

Info

Publication number
HK1025317A1
HK1025317A1 HK00104471A HK00104471A HK1025317A1 HK 1025317 A1 HK1025317 A1 HK 1025317A1 HK 00104471 A HK00104471 A HK 00104471A HK 00104471 A HK00104471 A HK 00104471A HK 1025317 A1 HK1025317 A1 HK 1025317A1
Authority
HK
Hong Kong
Prior art keywords
relates
derivatives
quinoxalinediones
quinoxalinedione
disorders
Prior art date
Application number
HK00104471A
Other languages
English (en)
Inventor
Alan Stobie
Elisabeth Colette Loui Gautier
David Charles Waite
Robert James Crook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1997/000995 external-priority patent/WO1997032873A1/fr
Priority claimed from GBGB9715783.8A external-priority patent/GB9715783D0/en
Priority claimed from PCT/EP1998/001275 external-priority patent/WO1998038186A1/fr
Application filed by Pfizer filed Critical Pfizer
Publication of HK1025317A1 publication Critical patent/HK1025317A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
HK00104471A 1997-02-27 2000-07-20 Quinoxalinediones HK1025317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP1997/000995 WO1997032873A1 (fr) 1996-03-09 1997-02-27 Quinoxalinediones
GBGB9715783.8A GB9715783D0 (en) 1997-02-27 1997-07-25 Quinoxalinediones
PCT/EP1998/001275 WO1998038186A1 (fr) 1997-02-27 1998-02-24 Quinoxalinediones

Publications (1)

Publication Number Publication Date
HK1025317A1 true HK1025317A1 (en) 2000-11-10

Family

ID=10816496

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00104471A HK1025317A1 (en) 1997-02-27 2000-07-20 Quinoxalinediones

Country Status (14)

Country Link
US (1) US6333326B1 (fr)
KR (1) KR100375112B1 (fr)
AP (1) AP982A (fr)
AU (1) AU723467B2 (fr)
DZ (1) DZ2437A1 (fr)
EA (1) EA001658B1 (fr)
GT (1) GT199800045A (fr)
HK (1) HK1025317A1 (fr)
IL (1) IL131120A0 (fr)
IS (1) IS5142A (fr)
MA (1) MA26474A1 (fr)
OA (1) OA11189A (fr)
PL (1) PL335501A1 (fr)
UA (1) UA58534C2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293503A4 (fr) * 2000-05-19 2008-04-02 Astellas Pharma Inc Derives de triazole
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
WO2008088820A2 (fr) 2007-01-16 2008-07-24 The Johns Hopkins University Antagonistes de récepteur de glutamate et procédés d'utilisation
CN104370834B (zh) 2007-05-17 2017-04-19 株式会社半导体能源研究所 三唑衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158846A (en) 1990-10-29 1992-10-27 Olin Corporation Electrostatic color printing system utilizing an image transfer belt
IT1243990B (it) * 1990-10-30 1994-06-28 Minnesota Mining & Mfg Procedimento per preparare prodotti del bisfenolo fluorene
EP0556393B1 (fr) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Derive de pyrazine fusionnee
GB9605027D0 (en) * 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones

Also Published As

Publication number Publication date
KR100375112B1 (ko) 2003-03-08
EA199900688A1 (ru) 2000-04-24
DZ2437A1 (fr) 2003-01-11
AP982A (en) 2001-07-16
GT199800045A (es) 1999-08-20
UA58534C2 (uk) 2003-08-15
KR20000075717A (ko) 2000-12-26
AU6827998A (en) 1998-09-18
OA11189A (en) 2003-05-14
US6333326B1 (en) 2001-12-25
PL335501A1 (en) 2000-04-25
AU723467B2 (en) 2000-08-24
IL131120A0 (en) 2001-01-28
IS5142A (is) 1999-07-30
MA26474A1 (fr) 2004-12-20
EA001658B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
WO1999026927A3 (fr) Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
IL157491A0 (en) Heteropolycyclic compounds and pharmaceutical compositions containing the same
EP1595871A3 (fr) Antagonistes du recepteur metabotrope duglutamate et leur utilisation pour le traitement des maladies du systeme nerveux central.
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
MY139523A (en) Ziprasidone composition and synthetic controls
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
EP1918287A3 (fr) Agonistes et antagonistes du récepteur lpa et méthodes d'utilisation
HUP0104018A3 (en) Pharmaceutical compositions containing antagonists of nr2b subtype of nmda receptor for treating neurological disorders
GB9815618D0 (en) Treatment of dyskinesia
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
HK1023770A1 (en) Chalcones having antiproliferative activity.
YU57999A (sh) N-triazolil-2-indolkarboksamidi i njihova primena kao agonista za cck-a
HK1049153A1 (en) Adenosine receptor antagonists and methods of making and using the same
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
WO2002039118A8 (fr) Procedes de criblage de mimetiques morphogenetiques osseux
HK1025317A1 (en) Quinoxalinediones
BG103649A (en) Method for the preparation of eprosartan
BG103650A (en) Method for the preparation of eprosartan
EP1335922A4 (fr) Nouveau derive de 4'-demethyl-4'-o-substitue-1-deoxypodophyllotoxine, isomere geometrique de celui-ci, procede de preparation de celui-ci, et composition anti-cancereuse comprenant ledit derive
ZA98682B (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
IL136949A0 (en) 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
PL370114A1 (en) Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists
ZA200004651B (en) Xylitol compositions for treating upper respiratory conditions.
ZA987182B (en) Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070224